{"schema_version":"secwatch.filing_event.v1","accession":"0001855644-26-000007","form_type":"8-K","ticker":"ZURA","cik":"0001855644","company_name":"Zura Bio Ltd","filed_at":"2026-08-11T11:35:33+00:00","discovered_at":"2026-08-11T11:40:00.297379+00:00","generated_at":"2026-08-11T11:40:06.313024+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Zura Bio completes enrollment in two Phase 2 tibulizumab trials; cash $205.1M","bullets":["TibuSHIELD (hidradenitis suppurativa) enrolled 247 participants, exceeding target; topline data Q4 2026.","TibuSURE (systemic sclerosis) enrolled 91 participants, exceeding target; topline data H1 2027.","New indication: plans Phase 2 NEXUS-PMR for polymyalgia rheumatica by year-end 2026.","Q2 2026 net loss $26.3M ($0.21/share) vs $16.0M ($0.17/share) in Q2 2025; R&D expenses $20.7M vs $8.7M.","Cash and equivalents $205.1M expected to fund operations through at least end of 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001855644-26-000007","json":"https://secwatch.observer/filing/0001855644-26-000007.json","markdown":"https://secwatch.observer/filing/0001855644-26-000007.md","text":"https://secwatch.observer/filing/0001855644-26-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855644/000185564426000007/0001855644-26-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855644/000185564426000007/zura-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T11:40:06.313024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}